RT Journal Article
SR Electronic
T1 The Role of ACKR3 in Breast, Lung, and Brain Cancer
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 819
OP 825
DO 10.1124/mol.118.115279
VO 96
IS 6
A1 Maria Neves
A1 Amos Fumagalli
A1 Jelle van den Bor
A1 Philippe Marin
A1 Martine J. Smit
A1 Federico Mayor
YR 2019
UL http://molpharm.aspetjournals.org/content/96/6/819.abstract
AB Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.